DUBLIN, April 18, 2019 /PRNewswire/ -- Alkermes plc
(Nasdaq: ALKS) will host a conference call and webcast presentation
at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 25, 2019, to discuss the company's
first quarter 2019 financial results. Management will also provide
an update on the company.
The webcast player and accompanying slides may be accessed on
the Investors section of Alkermes' website at www.alkermes.com. The
conference call may be accessed by dialing +1 877 407 2988 for U.S.
callers and +1 201 389 0923 for international callers.
A replay of the conference call will be available from
11:00 a.m. ET (4:00 p.m. BST) on Thursday, Apr. 25, 2019, through Thursday, May 2, 2019, and may be accessed by
visiting Alkermes' website or by dialing +1 877 660 6853 for U.S.
callers and +1 201 612 7415 for international callers. The replay
access code is 13690081.
About Alkermes plc
Alkermes plc is a fully
integrated, global biopharmaceutical company developing innovative
medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates
for chronic diseases that include schizophrenia, depression,
addiction, multiple sclerosis and oncology. Headquartered in
Dublin, Ireland, Alkermes plc has
an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in
Athlone, Ireland; and a
manufacturing facility in Wilmington,
Ohio. For more information, please visit Alkermes' website
at www.alkermes.com.
Alkermes Contact:
Alex Braun
Investor Relations
+1 781 296 8493
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg